Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations.
BACKGROUND
Mycophenolate mofetil has teratogenic properties in rats and rabbits. Previous human studies have reported an increased rate of fetal losses with its use. We report a case of major fetal malformations due to mycophenolate mofetil.


METHODS
The patient was treated with mycophenolate mofetil before conception and during the first trimester of pregnancy. The fetus had multiple malformations, specifically, facial dysmorphology and midline anomalies, including agenesis of the corpus callosum.


CONCLUSIONS
This case of fetal malformation attributable to mycophenolate mofetil must be taken into consideration when considering pregnancy in an organ-transplant recipient.
Le Ray
Camille
C
Department of Obstetrics and Gynecology, Hôpital Antoine Béclère, Clamart, France.
Coulomb
Aurore
A
Elefant
Elisabeth
E
Frydman
Rene
R
Audibert
François
F
D000014:Abnormalities, Drug-Induced / Q000473:pathology*; D000328:Adult; D000818:Animals; D005260:Female; D005333:Fetus / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011247:Pregnancy
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid